Clinical Trial to Explore Papilocare Gel Efficacy to Repair of the Cervico-vaginal Mucosa With HPV High Risk Lesions.

NACompletedINTERVENTIONAL
Enrollment

288

Participants

Timeline

Start Date

September 25, 2019

Primary Completion Date

January 31, 2024

Study Completion Date

June 30, 2024

Conditions
Human Papilloma VirusHuman Papilloma Virus InfectionCervix Lesion
Interventions
DEVICE

Papilocare vaginal gel

Papilocare is a gel vaginally administered by a singledose cannula. Vaginal gel formulation is effective as a local treatment with controlled systemic absorption and rapid and efficient distribution

Trial Locations (19)

14004

H. U. Reina Sofía, Córdoba

18014

Hospital Universitario Virgen de las Nieves, Granada

20014

Hospital U. de Donostia, Donostia / San Sebastian

28046

Hospital Universitario La Paz, Madrid

28938

Hospital Universitario HM Puerta del Sur, Móstoles

29010

H. R. U. de Málaga / Materno Infantil, Málaga

30202

H. General Universitario Santa Lucía, Murcia

36312

Hospital Álvaro Cunqueiro, Vigo

38010

Hospital Universitario Nuestra Señora de Candelaria, Santa Cruz de Tenerife

41009

Hospital Virgen de la Macarena, Seville

46026

Hospital Universitari i Politecnic La Fe, Valencia

48013

Hospital de Basurto, Bilbao

07120

Hospital Universitari Son Espases, Palma de Mallorca

03010

Hospital General Universitario de Alicante, Alicante

04009

Complejo Hospitalario Torrecárdenas, Almería

08003

Hospital del Mar, Barcelona

08035

Hospital Universitari Vall d' Hebron, Barcelona

08904

Assir Hospitalet de Llobregat, L'Hospitalet de Llobregat

Unknown

Hospital de Manacor, Manacor

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Adknoma Health Research

INDUSTRY

lead

Procare Health Iberia S.L.

INDUSTRY